LinkedIn: [Michael J. Martinelli](http://www.linkedin.com/in/michael-j-m-83a30262)
Professional Title and Role
Michael J. Martinelli serves as the Chief Medical Officer and Senior Vice President of Medical Affairs at Terumo Medical Corporation. He assumed this leadership role on or before February 26, 2020, as officially announced by the company. In this capacity, he oversees medical strategy, clinical affairs, and contributes significantly to the development and commercialization of new medical devices, particularly in interventional cardiology and vascular medicine.
Educational Background and Medical Credentials
- Doctor of Medicine (MD) awarded by the University of Health Sciences/The Chicago Medical School (Rosalind Franklin University).
- Holds the designations FACC (Fellow of the American College of Cardiology) and FSCAI (Fellow of the Society for Cardiovascular Angiography and Interventions).
- Completed undergraduate studies at the University of Notre Dame with a Bachelor of Science degree.
Clinical and Professional Expertise
- Over 31 years of clinical practice specializing in Interventional Cardiology.
- Previous extensive career as an Interventional Cardiologist at St. Peter’s Hospital in Albany, NY, including a tenure of 10 years in a leadership capacity.
- Recognized for expertise in complex percutaneous coronary interventions (PCIs) and vascular closure devices.
Contributions and Industry Impact
- Dr. Martinelli has played a central role in product launches and clinical studies at Terumo, promoting devices such as:
- Roadsaver Carotid Stent System (commercially available since May 2025),
- Peripheral R2P Navicross Support Catheter,
- Cross-Seal™ Suture-Mediated Vascular Closure Device,
- AZUR HydroPack™ Coil System — a platinum and hydrogel coil designed for occlusive filling of vascular spaces.
His statements and involvement highlight a hands-on role in clinical validation and product innovation supporting Terumo’s interventional portfolio.
- Identified as Medical Monitor on FDA clinical trial protocols sponsored by Terumo, underscoring his involvement in overseeing clinical research compliance and scientific rigor.
- Authored or contributed to over 200 peer-reviewed publications in the field of cardiology and vascular medicine, recognized as a leading surgeon-scientist and medical expert.
- Serves on editorial boards of key medical journals, enhancing Terumo’s visibility and influence in cardiology and interventional vascular disciplines.
Strategic Position and Influence
- As Chief Medical Officer, Dr. Martinelli provides medical oversight and strategic guidance aligned with Terumo’s product development and regulatory goals.
- His background merges clinical expertise with corporate leadership, positioning him as a critical stakeholder in evaluation and adoption of novel medical technologies relevant to Terumo’s growth targets in minimally invasive vascular interventions.
- Engaged in educational initiatives, including training and support for healthcare providers using Terumo’s radial access and vascular devices, echoing Terumo’s 30-year commitment to engineering and clinical education.
Recent Relevant Developments
- Under his medical leadership, Terumo Medical Corporation announced commercial availability of vital peripheral vascular and neurovascular devices, indicating active growth and innovation pipelines.
- The company’s public endorsements and product releases often feature Dr. Martinelli as the clinical authority, reflecting his stature as both a scientific and public-facing leader for Terumo.
Summary of Actionable Insights
- Dr. Michael J. Martinelli embodies a blend of deep clinical experience and executive oversight within Terumo Medical Corporation, holding pivotal responsibility for medical affairs and clinical innovation.
- His specialization in interventional cardiology and active involvement in clinical research and product launches underscores his direct influence on the direction of product adoption and clinical strategy.
- Any engagement or collaboration related to vascular device innovation or clinical trial initiatives would benefit from aligning with his proven expertise and leadership role.
- His participation in both regulatory oversight and medical education initiatives suggests openness to evidence-based clinical data and training support, critical factors for medical device acceptance.
References:
- Terumo Medical Corporation Press Releases (2023-2025)
- LinkedIn Announcement, February 2020
- Clinical trial protocol documents listing Dr. Martinelli as Medical Monitor
- Doximity Physician Profile
- Publication and editorial board data from professional industry sources
